Results from this study demonstrate a reduction in the proportion of patients requiring COPD/chronic bronchitis related readmission within 30 days and 12 months of the Aerobika® OPEP device therapy initiation compared to an alternative OPEP device.
This further supports the use of the Aerobika®OPEP device as an add-on to usual care to manage COPD/chronic bronchitis patients post-exacerbation and highlights that not all OPEP devices are the same in terms of 30-day and 12-month readmissions
Depending on the pMDI/spacer system chosen the delivery of medication can vary significantly and as a result will have implications on the potential carbon footprint.
In this case, the use of the AeroChamber Plus* Flow-Vu* VHC could potentially reduce the carbon footprint by three fold compared to the alternative spacers.
By maximizing the amount of each puff reaching the lungs the patient is likely to be able to get relief sooner and reduce the amount of puffs needed.
COPD/chronic bronchitis patients given an Aerobika* OPEP device compared to an alternative OPEP device had delayed time to re-admission. This supports use of the Aerobika* OPEP device as an add-on to usual care post-exacerbation and highlights differences in OPEP device effectiveness.
While it’s one of the most anticipated seasons of the year, summer can also be the most difficult season for Canadians living with COPD (chronic obstructive pulmonary disease). We want to help you make the most of it! Here’s what you need to know about summer, and how you can enjoy yours this year.
Chronic Obstructive Pulmonary Disease (COPD) affects around 251 million people globally.1 It is a term that covers two types of chronic (long-term) diseases where the airways in the lungs become “obstructed” or partly blocked.
Asthma is a chronic respiratory disease, characterized by narrowing of the airways and excess mucus production. People with asthma typically suffer from chest tightness/pain, shortness of breath, and episodes of coughing and wheezing.
Nontuberculous mycobacterial (NTM) lung disease is a chronic, progressive condition caused by nontuberculous mycobacteria. NTM lung disease occurs more frequently in older adults and people with other lung diseases, like bronchiectasis, and chronic obstructive pulmonary disease (COPD).
Cystic fibrosis (CF) is a progressive, genetic condition affecting more than 100,000 people worldwide.1 There are over 4,300 people living with CF in Canada.2
Bronchiectasis is a chronic, progressive lung condition affecting infants, children and adults. While the global prevalence of bronchiectasis is not accurately known,1 there is a growing awareness of the disease.2
If you suffer from Chronic Obstructive Lung Disease (COPD), simple tasks can start to feel larger than life. While there is no cure, there are steps you can take to improve your health and quality of life.
If you suffer from Chronic Obstructive Lung Disease (COPD), simple tasks can start to feel larger than life. While there is no cure, there are steps you can take to improve your health and quality of life.
The widely differing inspiratory flow profiles from Turbuhaler† DPI contributed to greater variability in delivered dose to the carina.
MDI delivery via the AeroChamber Plus* Flow-Vu* VHC resulted in significantly increased mass to the carinal region irrespective of inhalation maneuver as well as reduced oropharyngeal deposited mass which in vivo is likely to result in reduced throat irritation or thrush in the mouth and throat.
Medication delivery can vary significantly depending on the pMDI/spacer system which will have implications on the carbon footprint. In this case, the use of the AeroChamber Plus* Flow-Vu* spacer could potentially reduce the carbon footprint by up to five-fold compared to other spacers.
Have you ever struggled with chest congestion or a buildup of mucus in your chest? If so, you're not alone. Many people experience these uncomfortable symptoms, which can be caused by a variety of factors such as the common cold, allergies, asthma or COPD. The article below explores the role of mucus in chest congestion and discuss some ways to clear your airways.
The most efficient and effective delivery method remains that recommended in the device IFU (one actuation inhaled at a time, as well inhalation as soon as possible after actuation)
However, this laboratory-based study has indicated that a modified common-canister protocol with an anti-static VHC as the aerosol transfer vehicle has the potential to be a viable ‘off-label’ proposition in hospital situations where there is an urgent need to conserve pMDI medication as well as avoid cross-contamination from pathogenic viruses or bacteria
Have you ever struggled with chest congestion or a buildup of mucus in your chest? If so, you're not alone. Many people experience these uncomfortable symptoms, which can be caused by a variety of factors such as the common cold, allergies, asthma or COPD. The article below explores the role of mucus in chest congestion and discuss some ways to clear your airways.
The DPI results suggest that inhalation breathing profiles can have an appreciable impact upon aerosol delivery, with one participant having much less predicted medication as fine particles
In contrast, although the inhalation profiles across all participants were also divergent when asked to inhale from the pMDI + VHC, either tidal breathing or by a slow, deep inhalation, all volunteers would have received a relatively consistent amount of medication.
It also appears that the pMDI + VHC platform delivers a larger FPM<5.0 µm for both APIs and a consequently smaller coarse particle mass. However, it is recognized that more investigation is warranted with a larger number of volunteers and with other passive DPIs having different resistances
As the seasons change and the weather gets warmer, people with respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD) may face new challenges in managing their symptoms. Springtime can bring increased pollen and air pollution levels, which can trigger flare-ups and exacerbations in people with these conditions. However, with some proactive steps, it is possible to manage asthma and COPD effectively during the spring.
Presented at the British Thoracic Society December 2018.
Having a child with asthma can be stressful for parents, especially for financially strapped ones struggling to pay for an arsenal of puffers and pills for their child’s treatment. Because of this, those healthcare professionals who recommend spacer chambers may suggest one of many lower-cost versions that are available on the market today. But focusing only on cost may be putting a child’s health at risk.
As the seasons change and the weather gets warmer, people with respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD) may face new challenges in managing their symptoms. Springtime can bring increased pollen and air pollution levels, which can trigger flare-ups and exacerbations in people with these conditions. However, with some proactive steps, it is possible to manage asthma and COPD effectively during the spring.
